<DOC>
	<DOCNO>NCT02981342</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy abemaciclib alone combination drug versus standard care participant previously treat metastatic pancreatic ductal adenocarcinoma ( PDAC ) .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Alone Combination With Other Agents Participants With Previously Treated Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histological cytological diagnosis ductal adenocarcinoma pancreas . Metastatic disease document disease progression follow previous treatment least one , 2 prior therapy , one prior therapy either gemcitabinebased fluoropyrimidinebased therapy . Neoadjuvant and/or adjuvant therapy localize resectable unresectable PDAC count line therapy multiagent chemotherapy regimen administer ( neoadjuvant regimen different adjuvant regimen ) participant progress metastatic disease take within 6 month completion ( neo ) adjuvant therapy . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Participant treatment monotherapy chemotherapy gemcitabine capecitabine reasonable choice . Discontinued prior treatment cancer least 14 day prior initial dose study treatment . Adequate organ function . allow alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 5x upper limit normal ( ULN ) liver metastasis . allow bilirubin 2.5 time ULN elevation associate sign liver toxicity explain mechanical obstruction require clinical research physician approval . Severe cardiac disease : myocardial infarction within 6 month prior study screen , unstable angina pectoris , New York Heart Association Class III/IV congestive heart failure , uncontrolled hypertension . documented major electrocardiogram ( ECG ) abnormality , investigator 's discretion ( example , symptomatic sustain atrial ventricular arrhythmia , second thirddegree atrioventricular block , bundle branch block , ventricular hypertrophy , recent myocardial infarction ) , respond medical treatment clinically stable least 6 month prior study screen . major cardiac abnormality document echocardiography ( ECHO ) Doppler clinically stable least 6 month prior study screen ( example , severe heart valve function defect and/or leave ventricular ejection fraction [ LVEF ] &lt; 50 % , evaluation base institutional low limit normal ) . Predisposing condition consistent development aneurysm ascend aorta aortic stress ( example , family history aneurysm , MarfanSyndrome , bicuspid aortic valve , evidence damage large vessel heart document Computed Tomography [ CT ] scan magnetic resonance image [ MRI ] contrast ) . Have insulindependent diabetes mellitus . Participants type 2 diabetes mellitus eligible adequate control blood glucose level obtain oral antidiabetic document hemoglobin A1c ( HbA1c ) &lt; 7 % . Have symptomatic central nervous system metastasis . Screening asymptomatic participant require enrollment . Have major surgery within 7 day prior initiation study drug allow postoperative healing surgical wound site ( ) . Have previously receive treatment cyclindependent kinase ( CDK ) 4 6 inhibitor , transform growth factor beta ( TGFÎ² ) inhibitor , phosphatidylinositol 3kinase ( PI3K ) and/or mammalian target rapamycin ( mTOR ) inhibitor know hypersensitivity component investigational product study . Have know hypersensitivity gemcitabine capecitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>